scholarly journals Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study

Pulmonology ◽  
2020 ◽  
Author(s):  
F. Barata ◽  
H. Queiroga ◽  
E. Teixeira ◽  
T. Almodovar ◽  
M. Soares ◽  
...  
Keyword(s):  
Phase Ii ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Activating Mutations ◽  
Metastatic Nsclc ◽  
Nsclc Patients

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3658-3658
Author(s):  
T. H. Cartwright ◽  
T. Lopez ◽  
S. J. Vukelja ◽  
C. Encarnacion ◽  
K. A. Boehm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
First Line Treatment

Results of a Phase II Open-Label Study of Capecitabine in Combination with Irinotecan as First-Line Treatment for Metastatic Colorectal Cancer

2005 ◽  
Vol 5 (1) ◽  
pp. 50-56 ◽  
Author(s):  
Thomas Cartwright ◽  
Timothy Lopez ◽  
Svetislava J. Vukelja ◽  
Carlos Encarnacion ◽  
Kristi A. Boehm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
First Line Treatment

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3658-3658 ◽  
Author(s):  
T. H. Cartwright ◽  
T. Lopez ◽  
S. J. Vukelja ◽  
C. Encarnacion ◽  
K. A. Boehm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document